The genetic basis for variation in antibody response to vaccines

Current Opinion in Pediatrics

Volumn 10, Issue 2, 1998, Pages 208-215

  Poland, Gregory A ^a   Jacobson, Robert M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN; MEASLES VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ALLOTYPE; ANTIBODY RESPONSE; CHILD HEALTH; CLINICAL PRACTICE; GENE LOCUS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; MEASLES; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION;

EID: 0031831343     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199804000-00017     Document Type: Review

References (87)

1. Centers for Disease Control and Prevention: Measles - United States, 1990. MMWR 1991, 40:369-372.
2. Centers for Disease Control and Prevention: Measles - United States, 1989 and first 20 weeks 1990. MMWR 1990, 39:353-355, 361-363.
3. Poland GA, Jacobson RM: Failure to reach the goal of measles elimination: Apparent paradox of measles infections in immunized persons. Arch Intern Med 1994, 154:1815-1820.
4. Poland GA, Jacobson RM, Thanpy AM, Colboume SA, Wollan PC, Lipsky JJ, Jacobsen SJ: Measles re-immunization in children seronegative after initial immunization. JAMA 1997, 277:1156-1158.
5. ACP Task Force on Adult Immunization, Infectious Diseases Society of America: Guide for Adult Immunization, edn 3. Philadelphia, PA: American College of Physicians; 1994.
6. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Snydman DR, Platt R, Crumpacker CS, Grady GF, Alper CA: Nonresponsiveness to hepatitis B vaccine in health care workers: Results of revaccination and genetic tyings. Ann Intern Med 1986, 105:356-360.
7. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D: The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 1992, 175:495-502.
8. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ: Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989, 321:708-712.
9. Deulofeut H, Iglesias A, Mikael N, Bing DH, Awdeh Z, Yunis J, Marcus-Bagley D, Kruskall MS, Alper CA, Yunis EJ: Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated Individuals. Mol Immunol 1993, 30:941-948.
10. Caillat-Zucman S, Gimenez J-J, Albouze G, Lebkiri B, Naret C, Jungers P, Bach J-F: HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int 1993, 43:S157-S160.
11. Thursz MR, Kwiatkowski D, Allsopp CEM, Greenwood BM, Thomas HC, Hill AVS: Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995, 332:1065-1069.
12. Townsend A. Trowsdale J: The transporters associated with antigen presentation. Semin Cell Biol 1993, 4:53-61.
13. Spies T, DeMars R: Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature 1991, 351:323-324.
14. Suh W-K, Cohen-Doyle MF, Fruh K, Wang K, Peterson PA, Williams DB: Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 1994, 264:1322-1326.
15. Monaco JJ: Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 1995, 57:543-547.
16. Long EO, Jacobson S: Pathways of viral antigen processing and presentation to CTL: Defined by the mode of virus entry? Immunol Today 1989, 10:45-48.
17. Jackson MR, Peterson PA: Assembly and intracellular transport of MHC class I molecules. Annu Rev Cell Biol 1993, 9:207-235.
18. Cacalli-Sforza L, Menozzi P, Piazza A: The History and Geography of Human Genes. Princeton, NJ: Princeton University Press; 1994.
19. Pandey J: Genetics of immunoglobulins. In Introduction to Medical Immunology edn 3, edited by Virella G. Marcel Dekker; 1993: 103-116.
20. Pandey JP: Genetics of Immunoglobulins. Immunol Ser 1990, 50:107-121.
21. Steinberg AG, Cook CE: The Distribution of Human Immunoglobulin Allotypes, Cambridge; Oxford University Press; 1981.
22. Biggar RJ, Pandey JP, Henle W, Nkrumah FK, Levine PH: Humoral immune response to Epstein-Barr virus antigens and immunoglobulin allotypes in African Burkltt lymphoma patients. Int J Cancer 1994, 33:577-580.
23. De Vries RRP, Meera Kahn P, Bernini LF, van Lognem E, Van Rood JJ: Genetic control of survival in epidemics. J Immunogenet 1979, 6:271-287.
24. Goldblatt D, Scadding GK, Lund VJ, Wade AM, Turner MW, Pandey JP: Association of Gm allotypes with the antibody response to the outer membrane proteins of a common upper respiratory tract organism, Moraxella catarrhalis. J Immunol 1994, 153:5316-5320.
25. Granoff DM, Boies E, Squires J, Pandey JP, Suarez B, Oldfather J, Rodey GE: Interactive effect of genes associated with immunoglobulin allotypes and HLA specificities on susceptibility to Haemophilus influenzae disease. J Immunogenet 1994, 11:181-188.
26. Granoff DM, Pandey JP, Boies E, Squires J, Munson RS, Jr., Suarez B: Response to immunization with Haemophilus influenzae type b polysaccharide-pertussis vaccine and risk of Haemophilus meningitis in children with the Km(1) immunoglobulin allotype. J Clin Invest 1984, 74:1708-1714.
27. Granoff DM, Shackelford PG, Suarez BK, Nahm MH, Cates KL, Murphy TV, Karasic R, Osterholm MT, Pandey JP, Daum RS: Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine. N Engl J Med 1986, 315:1584-1590.
28. Grubb R, Christensen KK, Christensen P, Linden V: Association between maternal Gm allotype and neonatal septicaemia with group B streptococci. J Immunogenet 1982, 9:143-147.
29. Morell A, Vassalli G, DeLange GG, Skvaril F, Ambrosino DM, Siber GR: Ig allotype-linked regulation of class and subclass composition of natural antibodies to group A streptococcal carbohydrate. J Immunol 1989, 142:2495-2500.
30. Pandey JP, Baker CJ, Kasper DL, Fudenberg HH: Two unlinked genetic loci interact to control the human immune response to type III group B streptococcal antigen. J Immunogenet 1984, 11:159-163.
31. Pandey JP, Blaser MJ: Heterozygosity at the Km locus associated with humoral immunity to Campylobacter jejuni. Exp Clin Immunogenet 1986, 3:49-53.
32. Pandey JP, Elson LH, Sutherland SE, Guderian RH, Araujo E, Nutman TB: immunoglobulin kappa chain allotypes (KM) in onchocerciasis. J Clin Invest 1995, 96:2732-2734.
33. Wachsmuth RR, Pandey JP, Fedrick JA, Nishimura Y, Sasazuki T: Interactive effect of Gm and Km allotypes on cellular immune responses to streptococcal cell wall antigen. Exp Clin Immunogenet 1987, 4:163-166.
34. Whittingham S, Propert DN: Gm and Km allotypes, immune response and disease susceptibility. Monogr Allergy 1986, 19:52-70.
35. Black FL, Schiffman G, Pandey JP: HLA, Gm, and Km polymorphisms and immunity to infectious diseases In South Amerinds. Exp Clin Immunogenet 1995, 12:206-216.
36. Hope Simpson RE: Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952, 2:549-554.
37. Division of Microbiology and Infectious Diseases, National Institutes of Health: Annual Report: The Jordan Report: Accelerated Development of Vaccines 1995.
38. Centers for Disease Control and Prevention: Measles prevention: Recommendations of the immunization practices advisory committee (ACIP). MMWR 1989, 38:11-14.
39. Wharton M, Cochi SL, Williams WW: Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 1990, 4:47-73.
40. Preblud SR, Katz SL: Measles vaccine. In Vaccines, Edited by Rotkin SA, Mortimer EA, Jr. Philadelphia, PA: W.B. Saunders, Co. 1988:182-222.
41. Brunell PA, Weigle K, Murphy D, Shehab Z, Cobb E: Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 1983, 250:1409-1412.
42. Orenstein WA, Herrmann K, Albrecht P, Bernier R, Holmgreen P, Bart KJ, Hinman AR: Immunity against measles and rubella in Massachusetts schoolchildren. Develop Biol Standard 1986, 65:75-83.
43. Poland GA, Jacobson RM, Rabe D, Lipsky JJ, Wollan PC: The association between measles vaccine and mumps vaccine failure in a cohort of U.S. school children [abstract]. Abstracts of the 35th ICAAC 1995, :184-#H24.
44. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC: Secondary failure rates of measles vaccines: A meta-analysis of published studies. Pediatr Infect Dis J 1996, 15:62-66.
45. Hayney MS, Poland GA, Dimanlig P, Schaid DJ, Jacobson RM, Lipsky JJ: Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 1997, 15:3-6. This study is the first to demonstrate a relationship between vaccine response and polymorphisms of the human TAP gene.
46. .13 allele plays in immune responses. Previous work demonstrated similar relationships in other infectious disesases.
47. Hayney MS, Schaid DJ, Jacobson RM, Lipsky JJ, Poland GA: Association of measles vaccine nonresponse and class II HLA-DR alleles [abstract]. Abstracts of the 34th ICAAC 1994, :240-#H109.
48. Poland GA, Hayney MS, Schaid DJ, Jacobson RM, Lipsky JJ: Class II HLA-DR homozygosity is associated with non-response to measles vaccine in U.S. children [abstract]. FASEB J 1995, 9:A240-#1397.
49. .13 allele may be a marker for measles vaccine failure [abstract]. J Invest Med 1995, 43:486A.
50. Hayney MS, Poland GA, Jacobson RM, Rabe D, Schaid DJ, Jacobsen SJ, Lipsky JJ: The relationship of HLA-DQA1 alleles and humoral antibody following measles vaccination. Int J Infect Dis 1998, 2:143-146. This study determined the relationship between measles vaccine response and polymorphisms of the DQA1 allele, as well as DQA1 homozygosity.
51. Poland GA, Jacobson RM, Schaid DJ, Jacobsen SJ: The association between HLA class I alleles and measles vaccine-induced antibody response: Evidence of a significant association. Vaccine 1997, (In Press) The largest study to date examining the role of the class I alleles in measles vaccine response.
52. Mineta M, Tanimura M, Tana T, Yssel H, Kashiwagi S, Sasazuki T: Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans. Int Immunol 1996, 8:525-531. An excellent methodologic study demonstrating the association between class I and class II HLA genes and hepatitis B vaccine nonresponse in Japanese subjects.
53. Chiou S-S, Yamauchi K, Nakanishi T, Obata H: Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology 1988, 64:545-550.
54. Watanabe H, Okumura M, Hirayama K, Sasazuki T: HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells. Tissue Antigens 1990, 36:69-74.
55. + suppressor T cells. Hum Immunol 1988, 22:9-17.
56. Rodriguez-Barradas MC, Groover JE, Lacvke CE, Gump DW, Lahart CJ, Pandey JP, Musher DM: IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: Persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996, 173:1347-1353. The authors found a strong association between Km(1)-negative allotypes and response to pneumococcal polysaccharide vaccine in white, HIV-infected men. They did not find an association with Gm(23)-positive allotypes or any other Gm allotypes.
57. Ambrosino DM, Barrus VA, DeLange GG, Siber GR: Correlation of the Km(1) immunoglobulin allotype with anti-polysaccharide antibodies in caucasian adults. J Clin Invest 1986, 78:361-365.
58. Musher DM, Groover JE, Watson DA, Pandey JP, Rodriguez-Barradas MC, Baughn RE, Pollack MS, Graviss EA, de Andrade M, Amos CI: Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Invest Med 1997, 45:57-68. The authors found a strong association between Gm(23)-positive allotypes and response to pneumococcal polysaccharide vaccine in white, non-Jewish adults. They found no association in a large Ashkenazic family, nor did they find any association with Km allotypes.
59. Pandey JP, Fudenberg HH, Virella G, Kyong CU, Loadholt CB, Galbraith RM: Association between immunoglobulin allotypes and immune responses to Haemophilus influenzea and meningococcus polysaccharides. Lancet 1979, 1:190-192.
60. Sarvas H, Rautonen N, Sipinen S, Mäkelä O: IgG subclasses of pneumococcal antibodies-effect of allotype G2m(n). Scand J Immunol 1989, 29:229-237.
61. Weinberg GA, Granoff DM: Immunogenicity to Haemophilus influenzae type b polysaccharide conjugate vaccines in children with conditions associated with impaired antibody responses to type b polysaccharide vaccine. Pediatrics 1990, 85:654-661.
62. Ambrosino DM, Schiffman G, Gotschlich EC, Schur PH, Rosenberg GA, DeLange GG, van Loghem E, Siber GR: Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J Clin Invest 1985, 75:1935-1942.
63. Granoff DM, Suarez BK, Pandey JP, Shackelford PG: Genes associated with G2m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 1988, 157:1142-1149.
64. Rota JS, Heath JL, Rota PA, King GE, Celma ML, Carabaña J, Fernandez-Muñoz R, Brown D, Jin L, Bellini WJ: Molecular epidemiology of measles virus: Identification of pathways of transmission and implications for measles elimination. J Infect Dis 1996, 173:32-37.
65. Rota JS, Wang Z-D, Rota PA, Bellini WJ: Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 1994, 31:317-330.
66. Rota JS, Hummel KB, Rota PA, Bellini WJ: Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology 1992, 188:135-142.
67. Tamin A, Rota PA, Wang Z, Heath JL, Anderson LJ, Bellini WJ: Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 1994, 170:795-801.
68. Rota PA, Bloom AE, Vanchiere JA, Bellini WJ: Evolution of the nucleoprotein and matrix genes of wild-type strains of measles virus isolated from recent epidemics. Virology 1994, 198:724-730.
69. Hedrick PW: Evolution at HLA: Possible explanations for the deficiency of homozygotes in two populations. Hum Hered 1990, 40:213-220.
70. Black FL, Salzano FM: Evidence for heterosis in HLA system. Am J Hum Genet 1981, 33:894-899.
71. Black FL, Pinheiro FD, Hierholzer WJ, Lee RV: Epidemiology of infectious disease: The example of measles. In Health and Disease in Tribal Societies, Anonymous. Amsterdam: Elsevier; 1977:115-135.
72. Hayney MS, Jacobson RM, Lipsky JJ, Schaid DJ, Poland GA: Is TAP gene polymorphism important in measles vaccine response [abstract]? Abstr 34th Intersci Conf Antimicrob Agents Chemother 1994, :229-#H52.
73. Dimanlig P, Hayney MS, Lipsky JJ, Jacobson RM, Schaid DJ, Poland GA: The influence of TAP gene polymorphisms on the antibody response to live measles vaccine virus: Preliminary results [abstract]. Cold Spring Harbor Laboratory Conference on Molecular Approaches to the Control of Infectious Diseases. 1994:53.
74. Hayney MS, Dimanlig P, Lipsky JJ, Jacobson RM, Poland GA: TAP2 allele heterozygosity at position 665 may predict measles vaccine antibody response [abstract]. FASEB J 1995, 9:A240-#1398.
75. Hansen TH, Carreno BM, Sachs DH: The major histocompatibility complex. In Fundamental Immunology, edn 3. Edited by Paul WE. New York: Raven Press; 1993:577-628.
76. Hughes AL, Nei M: Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 1988, 335:167-170.
77. Kruskall MS: The major histocompatibility complex: The value of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med 1990, 63:477-486.
78. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE: Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the caucasian population. Biochemistry 1995, 34:10130-10138.
79. Nepom GT, Domeier ME, Ou D, Kovats S, Mitchell LA, Tingle AJ: Recognition of contiguous allele-specific peptide elements in the rubella virus E1 envelope protein. Vaccine 1997, 15:648-652.
80. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH: Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo. Identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 1997, 159:1362-1373.
81. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, Keogh E, Appella E, Nutman TB, Lal AA, Gordon DM, Oloo A, Sette A: Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 1997, 7:97-112.
82. Riley EM: The role of MHC-and non-MHC-associated genes in determining the human immune response to malaria antigens. Parasitology 1996, 112:539-351.
83. Gorse GJ, Patel GB, Newman FK, Mandava M, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network: Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. Vaccine 1995, 13:1170-1179.
84. Becker Y: HIV-peplotion vaccine: A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection. In Novel Strategies in Design and Production of Vaccines, Edited by Cohen S, Shafferman A. New York: Plenum Press; 1996:97-104.
85. Threlkeld SC, Wentworth PA, Kalams SA, Wilkes BM, Ruhl DJ, Keogh E, Sidney J, Southwood S, Walker BD, Sette A: Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-llke superfamily: Implications for vaccine development. J Immunol 1997, 159:1648-1657. An interesting conceptual approach to the development of vaccines.
86. Davenport MP, Hill AVS: Reverse immunogenetics: From HLA-disease associations to vaccine candidates. Mol Med Today 1996, 2:38-45.
87. Gulukota K, DeLisi C: HLA allele selection for designing peptide vaccines. Genet Anal 1997, 13:81-86. The authors demonstrate a quantitative approach for designing peptide subunit vaccines based on knowledge of HLA frequencies and antigen binding.